meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1)
2
mCRC - 2nd line (L2)
3
endometrial cancer
10
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
avelumab based treatment
avelumab plus SoC
dostarlimab based treatment
dostarlimab plus soC
durvalumab based treatment
durvalumab plus olaparib plus SoC
durvalumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus lenvatinib
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
talazoparib
VEGF(R) inhibitor
lenvatinib
lenvatinib in association
no study with result for this clinical condition